Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New add-on therapy for kidney cancer

  • Comment

An add-on therapy for treating kidney cancer patients has been launched in the UK.

Bevacizumab (Avastin) is a first-line treatment for patients with advanced renal cell cancer in combination with interferon.

Its manufacturer, Roche, said the drug combination doubled progression free survival from a median of 5.4 months with interferon alone to 10.2 months. Overall survival data is still being collected, the company said.

NICE guidance on renal cell carcinoma is expected in January 2009.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.